Article Text
Abstract
Almost any medicine can be purchased online from abroad. Many high-income countries permit individuals to import medicines for their personal use. However, those who import medicines face the risk of purchasing poor-quality products that may not work, or that may even harm them. Many people are willing to accept this risk for the opportunity to purchase more affordable medicines. This is especially true of individuals from low socioeconomic backgrounds who already struggle to afford the medicines they need if they are not subsidised by insurers or if copayments are high. As medicine prices and out-of-pocket healthcare spending continue to climb, the online marketplace provides an important alternative for individuals in high-income countries to source medicines. In this article, I argue that doctors have a responsibility to help patients access medicines online and I propose a framework that can be used to facilitate responsible personal importation.
- ethics- medical
- human rights
- quality of health care
- right to health
- drug industry
Data availability statement
No data are available.
Statistics from Altmetric.com
Data availability statement
No data are available.
Footnotes
Contributors NG is responsible for the conceptualisation, analysis and writing of this manuscript and is guarantor of the overall content.
Funding This work is supported by a Macquarie University Research Fellowship.
Competing interests None declared.
Provenance and peer review Not commissioned; externally peer reviewed.
Read the full text or download the PDF:
Other content recommended for you
- Off-label use of bevacizumab in the treatment of retinal disease: ethical implications
- Why have UK doctors been deterred from prescribing Avastin?
- Implications of “not me” drugs for health systems: lessons from age related macular degeneration
- Plasma levels of vascular endothelial growth factor before and after intravitreal injection of bevacizumab, ranibizumab and pegaptanib in patients with age-related macular degeneration, and in patients with diabetic macular oedema
- Bevacizumab for neovascular age related macular degeneration (ABC Trial): multicentre randomised double masked study
- Cluster endophthalmitis due to Stenotrophomonas maltophilia following intravitreal bevacizumab: outcomes of patients from North India
- Are the odds shifting against pharma in the fight for cheaper treatment for macular degeneration?
- Brolucizumab: the road ahead
- Why using Avastin for eye disease is so difficult
- Vascular endothelial growth factor inhibition in uveitis: a systematic review